UNITAID
has announced the second
Call for Letters of Intent (LOI) of its 2013-2016 strategic period. UNITAID is a global health initiative, established to provide sustainable, predictable and additional funding to significantly impact on market dynamics to reduce prices and increase the availability and supply of high quality commodities for the prevention, diagnosis, and treatment of HIV/AIDS, malaria, and tuberculosis, primarily for people living in low-resource settings. In 2013 UNITAID approved over $160 million in funding.
The UNITAID funding process begins with an
LOI: a short conceptual presentation of a proposed project that is submitted to
UNITAID electronically using a web-based tool. Proponents with successful LOIs
are then invited to submit full proposals for UNITAID funding.
This Call for LOIs is open to interventions
supporting any one of the six Strategic Objectives outlined in UNITAID’s 2013-2016 Strategy.
LOIs must be submitted to UNITAID by 17:00 Geneva (Switzerland) time (GMT+1) on
15 May 2014. The LOI is submitted electronically through the UNITAID homepage. Proponents will be notified by early June 2014 as to whether they
will be invited to submit a full project proposal for UNITAID funding. Full
project proposals will be due in early September 2014.
To submit an LoI, register at the UNITAID homepage.
For full details about the call for letters of intent, and further instructions, click here.
About UNITAID:
UNITAID focuses on markets and market-based approaches
because access to health products is often inhibited by one or more market
shortcomings that can only be corrected with targeted intervention. By
correcting these shortcomings, UNITAID works to decrease prices, improve
quality, and improve acceptability of products, and these positive
externalities ensure other countries and purchasers have access to improved,
more affordable public health commodities.
UNITAID strategic objectives:
- Increase access to simple, POC diagnostics for HIV/AIDS, TB and malaria.
- Increase access to affordable, paediatric medicines to treat HIV/AIDS, TB and malaria.
- Increase access to emerging medicines and/or regimens, as well as new formulations, dosage forms, or strengths of existing medicines that will improve the treatment of HIV/AIDS and co-infections such as viral hepatitis.
- Increase access to artemisinin-based combination therapies (ACTs) and emerging medicines, that, in combination with appropriate diagnostic testing, will improve the treatment of malaria.
- Secure supply of second-line TB medicines, and increase access to emerging medicines and regimens that will improve treatment of both drug-sensitive and multi drug-resistant TB.
- Increase access to products for the prevention of HIV, TB, and malaria.
